tirzepatide drugs New Breakthrough Obesity Drug Users of Zepbound or Mounjaro

The SURMOUNT-1 trial recorded 22.5% average weight loss at this dose, roughly 52 pounds

Honest Peptide is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under section 503B

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing

How Tirzepatide Supports Weight Loss Tirzepatide works through two hormone pathways: GLP-1 and GIP